Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 61.14
BTX's Cash to Debt is ranked higher than
50% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. BTX: 61.14 )
Ranked among companies with meaningful Cash to Debt only.
BTX' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 10000.00 Max: No Debt
Current: 61.14
Equity to Asset 0.28
BTX's Equity to Asset is ranked lower than
87% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. BTX: 0.28 )
Ranked among companies with meaningful Equity to Asset only.
BTX' s Equity to Asset Range Over the Past 10 Years
Min: -17.41  Med: 0.30 Max: 0.93
Current: 0.28
-17.41
0.93
F-Score: 4
Z-Score: -2.41
M-Score: -2.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -934.69
BTX's Operating margin (%) is ranked lower than
78% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -66.05 vs. BTX: -934.69 )
Ranked among companies with meaningful Operating margin (%) only.
BTX' s Operating margin (%) Range Over the Past 10 Years
Min: -1262.65  Med: -343.57 Max: -116.83
Current: -934.69
-1262.65
-116.83
Net-margin (%) -666.31
BTX's Net-margin (%) is ranked lower than
76% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -68.08 vs. BTX: -666.31 )
Ranked among companies with meaningful Net-margin (%) only.
BTX' s Net-margin (%) Range Over the Past 10 Years
Min: -989.69  Med: -337.07 Max: -137.48
Current: -666.31
-989.69
-137.48
ROE (%) -197.81
BTX's ROE (%) is ranked lower than
92% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. BTX: -197.81 )
Ranked among companies with meaningful ROE (%) only.
BTX' s ROE (%) Range Over the Past 10 Years
Min: -381.18  Med: -142.42 Max: -49.44
Current: -197.81
-381.18
-49.44
ROA (%) -59.27
BTX's ROA (%) is ranked lower than
76% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. BTX: -59.27 )
Ranked among companies with meaningful ROA (%) only.
BTX' s ROA (%) Range Over the Past 10 Years
Min: -624.96  Med: -63.91 Max: -33.33
Current: -59.27
-624.96
-33.33
ROC (Joel Greenblatt) (%) -1280.44
BTX's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. BTX: -1280.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BTX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -20611.76  Med: -2458.00 Max: -1265.92
Current: -1280.44
-20611.76
-1265.92
Revenue Growth (3Y)(%) 3.20
BTX's Revenue Growth (3Y)(%) is ranked lower than
52% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. BTX: 3.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BTX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -51.6  Med: 8.00 Max: 98.3
Current: 3.2
-51.6
98.3
EBITDA Growth (3Y)(%) 18.40
BTX's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 497 Companies
in the Global Biotechnology industry.

( Industry Median: -0.30 vs. BTX: 18.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BTX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.5  Med: 8.00 Max: 70.2
Current: 18.4
-48.5
70.2
EPS Growth (3Y)(%) 11.00
BTX's EPS Growth (3Y)(%) is ranked higher than
70% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. BTX: 11.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BTX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.1  Med: 9.80 Max: 64
Current: 11
-35.1
64
» BTX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-07)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

BTX Guru Trades in

Q2 2014

BTX Guru Trades in Q2 2014

Jim Simons Sold Out
» More
Q2 2015

BTX Guru Trades in Q2 2015

Jim Simons 165,000 sh (New)
» More
Q3 2015

BTX Guru Trades in Q3 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.81
BTX's P/B is ranked lower than
84% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. BTX: 9.81 )
Ranked among companies with meaningful P/B only.
BTX' s P/B Range Over the Past 10 Years
Min: 5.24  Med: 10.74 Max: 45.84
Current: 9.81
5.24
45.84
P/S 32.85
BTX's P/S is ranked lower than
73% of the 674 Companies
in the Global Biotechnology industry.

( Industry Median: 11.42 vs. BTX: 32.85 )
Ranked among companies with meaningful P/S only.
BTX' s P/S Range Over the Past 10 Years
Min: 4.2  Med: 37.17 Max: 106.11
Current: 32.85
4.2
106.11
Current Ratio 3.79
BTX's Current Ratio is ranked lower than
57% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. BTX: 3.79 )
Ranked among companies with meaningful Current Ratio only.
BTX' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 3.90 Max: 29
Current: 3.79
0.03
29
Quick Ratio 3.79
BTX's Quick Ratio is ranked lower than
55% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. BTX: 3.79 )
Ranked among companies with meaningful Quick Ratio only.
BTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 3.90 Max: 27
Current: 3.79
0.03
27
Days Inventory 74.12
BTX's Days Inventory is ranked higher than
68% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 120.79 vs. BTX: 74.12 )
Ranked among companies with meaningful Days Inventory only.
BTX' s Days Inventory Range Over the Past 10 Years
Min: 44.02  Med: 75.44 Max: 540.98
Current: 74.12
44.02
540.98
Days Sales Outstanding 85.29
BTX's Days Sales Outstanding is ranked lower than
63% of the 603 Companies
in the Global Biotechnology industry.

( Industry Median: 66.24 vs. BTX: 85.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
BTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 85.34  Med: 91.79 Max: 98.84
Current: 85.29
85.34
98.84
Days Payable 923.39
BTX's Days Payable is ranked higher than
99% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 63.23 vs. BTX: 923.39 )
Ranked among companies with meaningful Days Payable only.
BTX' s Days Payable Range Over the Past 10 Years
Min: 922.56  Med: 1001.68 Max: 5165.44
Current: 923.39
922.56
5165.44

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.88
BTX's Price/Median PS Value is ranked higher than
52% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. BTX: 0.88 )
Ranked among companies with meaningful Price/Median PS Value only.
BTX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 1.21 Max: 26.65
Current: 0.88
0.13
26.65
Price/Graham Number 2.95
BTX's Price/Graham Number is ranked lower than
60% of the 292 Companies
in the Global Biotechnology industry.

( Industry Median: 2.51 vs. BTX: 2.95 )
Ranked among companies with meaningful Price/Graham Number only.
BTX' s Price/Graham Number Range Over the Past 10 Years
Min: 0.62  Med: 1.97 Max: 17
Current: 2.95
0.62
17
Earnings Yield (Greenblatt) (%) -23.19
BTX's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. BTX: -23.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BTX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -29.72  Med: 0.00 Max: 0
Current: -23.19
-29.72
0

More Statistics

Revenue(Mil) $7
EPS $ -0.59
Beta1.49
Short Percentage of Float14.18%
52-Week Range $2.02 - 5.40
Shares Outstanding(Mil)94.89

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 8 8
EPS($) -0.66 -0.62
EPS without NRI($) -0.66 -0.62

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:RPTP, NAS:ARNA, NAS:BPMC, NAS:XBIT, XKRX:031390, XKRX:049960 » details
Traded in other countries:BT3.Germany, BTX.Israel,
BioTime Inc was incorporated in 1990 in the state of California. It is a biotechnology company engaged in two areas of biomedical research and product development. Its main focus is in the field of regenerative medicine; specifically human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. Its core technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. Products made from these pluripotent stem cells are being developed by the Company and its subsidiaries, for use in various fields of medicine, including: neuroscience, oncology, orthopedics, and blood and vascular diseases. HyStem, Hextend, ESpy, PureStem, and PentaLyte are registered trademarks of the Company and Renevia, Premvia, ReGlyde, and ESpan are trademarks of the Company.
» More Articles for BTX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

More From Other Websites
BioTime Co-CEO Dr. Michael West Presents at Biomedical Innovation for Healthy Longevity,... Apr 26 2016
BioTime Co-CEO Dr. Michael West Presents at Biomedical Innovation for Healthy Longevity,... Apr 26 2016
LifeMap Solutions Launches Full-Service Mobile Health App Design & Development to Meet the Needs of... Apr 25 2016
LifeMap Solutions Launches Full-Service Mobile Health App Design & Development to Meet the Needs of... Apr 25 2016
ETF’s with exposure to BioTime, Inc. : April 19, 2016 Apr 19 2016
BIOTIME INC Files SEC form 8-K, Change in Directors or Principal Officers Apr 15 2016
BioTime Co-CEO Dr. Michael West to Present at Stem Cells in Drug Discovery 2016 in Cambridge, UK Apr 05 2016
BioTime Co-CEO Dr. Michael West to Present at Stem Cells in Drug Discovery 2016 in Cambridge, UK Apr 05 2016
BioTime Co-CEO Dr. Michael West to Present at Stem Cells in Drug Discovery 2016 in Cambridge, UK Apr 05 2016
BioTime, Inc. :BTX-US: Earnings Analysis: 2015 By the Numbers Mar 24 2016
BioTime, Inc. to Host Conference Call to Update Investors on Recent Accomplishments and Corporate... Mar 21 2016
BioTime, Inc. to Host Conference Call to Update Investors on Recent Accomplishments and Corporate... Mar 21 2016
BIOTIME INC Financials Mar 19 2016
BIOTIME INC Files SEC form 10-K, Annual Report Mar 15 2016
BIOTIME INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 03 2016
Asterias Biotherapeutics Appoints Stephen L. Cartt President and Chief Executive Officer Feb 29 2016
BioTime Subsidiary Asterias Biotherapeutics Reports the Successful End-of-Phase II FDA Meeting for... Feb 24 2016
Coverage initiated on BioTime by Chardan Capital Markets Feb 19 2016
BIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Feb 18 2016
BioTime and Asterias Sign Share Transfer Agreement and Cross-License Agreement for Pluripotent Stem... Feb 16 2016
BioTime, Inc. to Present at Three Investor Conferences in February Feb 01 2016
BioTime, Inc. to Present at Three Investor Conferences in February Feb 01 2016
BIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 27 2016
LifeMap Sciences, a Subsidiary of BioTime, Announces the Launch of TGex™, the Knowledge-Driven NGS... Jan 20 2016
Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018 Jan 12 2016
BIOTIME INC Files SEC form 8-K, Material Modification to Rights of Security Holders, Financial... Jan 12 2016
Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018 Jan 12 2016
BioTime, Inc. breached its 50 day moving average in a Bearish Manner : January 5, 2016 Jan 05 2016
BioTime Completes Distribution of Approximately 4.75 Million Shares of OncoCyte Corporation Common... Dec 31 2015
BIOTIME INC Files SEC form 8-K, Other Events Dec 31 2015
BioTime Completes Distribution of Approximately 4.75 Million Shares of OncoCyte Corporation Common... Dec 31 2015
BioTime Announces “When-Issued” Trading of Subsidiary OncoCyte Corporation in Connection With... Dec 30 2015
BioTime Co-Chief Executive Officer Michael D. West, PhD to Deliver Keynote Speech at the 2015 World... Dec 11 2015
BioTime, Inc. Announces Record Date, Distribution Ratio, and Distribution Date for Distribution of... Dec 11 2015
BioTime, Inc. to Present at Oppenheimer Annual Healthcare Conference Dec 04 2015
LifeMap Solutions Launches COPD Navigator App for Consumers and Commercial Partners Dec 03 2015
LifeMap Solutions Appoints Robert W. Peabody Chief Financial Officer Nov 24 2015
BioTime, Inc. Announces the Appointment of Life Sciences Industry Veteran Russell Skibsted as Chief... Nov 18 2015
BioTime, Inc. Reports Third Quarter 2015 Results and Recent Corporate Accomplishments Nov 09 2015
BioTime, Inc. and Hepregen Corporation Form Ascendance Biotechnology, Inc. to Address the In Vitro... Nov 06 2015
LifeMap Sciences, a Subsidiary of BioTime, and Lab7 Systems Announce Partnership and Launch of... Nov 04 2015
LifeMap Sciences’ NGS Analysis and Interpretation Tools VarElect and GeneAnalytics™ Licensed by... Oct 08 2015
BioTime’s Subsidiary OncoCyte Corporation Files Form 10 Registration Statement for Planned... Oct 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK